TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model

[1]  Ryuzo Ueda,et al.  CCR4 as a novel molecular target for immunotherapy of cancer , 2006, Cancer science.

[2]  Yusuke Nakamura,et al.  Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Y. Yonemitsu,et al.  Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-β Gene1 , 2006, The Journal of Immunology.

[4]  S. Xiong,et al.  Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF , 2006, Cancer Gene Therapy.

[5]  R. Pawankar,et al.  Increased Expression of RANTES, CCR3 and CCR5 in the Lesional Skin of Patients with Atopic Eczema , 2006, International Archives of Allergy and Immunology.

[6]  D. Pardoll,et al.  GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men , 2006, International reviews of immunology.

[7]  Jonathan K. H. Tan,et al.  Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity , 2005, Journal of leukocyte biology.

[8]  R. Costello,et al.  Éosinophiles et réponse antitumorale , 2005 .

[9]  N. Krug,et al.  The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. , 2005, The Journal of clinical investigation.

[10]  G. Dranoff.  CTLA-4 blockade: unveiling immune regulation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Escher,et al.  Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases , 2004, Allergy.

[12]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[13]  M. Lifton,et al.  Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. , 2004, The Journal of clinical investigation.

[14]  M. Noguchi,et al.  Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[16]  D. Carbone,et al.  Lung cancer vaccines and gene therapy. , 2003, Lung cancer.

[17]  D. Neuberg,et al.  Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[19]  R. DeMatteo,et al.  Endogenous Granulocyte-Macrophage Colony-Stimulating Factor Overexpression In Vivo Results in the Long-Term Recruitment of a Distinct Dendritic Cell Population with Enhanced Immunostimulatory Function1 , 2002, The Journal of Immunology.

[20]  P. Murphy.  International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature , 2002, Pharmacological Reviews.

[21]  G. Hartmann,et al.  Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo1 , 2000, The Journal of Immunology.

[22]  F. Marshall,et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.

[23]  F. Sallusto,et al.  Three chemokines with potential functions in T lymphocyte‐independent and ‐dependent B lymphocyte stimulation , 1999, European journal of immunology.

[24]  H. Hamada,et al.  Activated dendritic cells from bone marrow cells of mice receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing syngeneic tumors. , 1999, Blood.

[25]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Kielian,et al.  Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice , 1998, Cancer Immunology, Immunotherapy.

[27]  S. Asano,et al.  Vaccine effect of granulocyte–macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity , 1998, Gene Therapy.

[28]  M. Baggiolini,et al.  CCR5 is characteristic of Th1 lymphocytes , 1998, Nature.

[29]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[30]  D. Longo,et al.  Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. , 1996, Journal of immunology.

[31]  M. Baggiolini,et al.  Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. , 1996, Journal of immunology.

[32]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[34]  J. Banchereau,et al.  GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells , 1992, Nature.

[35]  J. Ritz,et al.  Biology and clinical relevance of human natural killer cells. , 1990, Blood.

[36]  G. Schuler,et al.  Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells , 1988, The Journal of experimental medicine.

[37]  R. Steinman,et al.  Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells , 1987, The Journal of experimental medicine.

[38]  R. Costello,et al.  [Eosinophils and antitumour response]. , 2005, La Revue de medecine interne.

[39]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  G. Haas,et al.  Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. , 2001, Journal of immunotherapy.

[41]  K. Matsushima,et al.  Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. , 1999, International immunology.

[42]  T. Hirano.  Interleukin 6 and its receptor: ten years later. , 1998, International reviews of immunology.

[43]  P. Ricciardi-Castagnoli,et al.  Recombinant GM-CSF induces cytokine production in mouse dendritic cell clones. , 1995, Advances in experimental medicine and biology.

[44]  R. Steinman,et al.  Dendritic cells: antigen presentation, accessory function and clinical relevance. , 1993, Advances in experimental medicine and biology.

[45]  J. Banchereau,et al.  GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. , 1992, Nature.

[46]  G. Schuler,et al.  Dendritic cell production of cytokines and responses to cytokines. , 1990, International reviews of immunology.